Therapeutic area
GLP-1 & obesity
Semaglutide, tirzepatide, retatrutide, orforglipron, plus Novo Nordisk, Eli Lilly, Roche, Pfizer obesity programs. Tracks trials, FDA mentions, FAERS trends, 8-K disclosures.
Load template →
Therapeutic area
Oncology checkpoint inhibitors
PD-1, PD-L1, CTLA-4, LAG-3, TIGIT, plus Merck, BMS, AstraZeneca, Regeneron programs. Trial movement, results, safety, EDGAR disclosure.
Load template →
Therapeutic area
Alzheimer's disease
Donanemab, lecanemab, anti-amyloid + anti-tau. Trial status, results posting, FDA advisory committee notices, safety surveillance.
Load template →
Modality
Rare-disease gene therapies
AAV-based programs, ex vivo gene-edited, in vivo CRISPR. Sarepta, BioMarin, Sangamo, CRISPR Therapeutics, Editas. Trial movement, safety, EDGAR.
Load template →
Operational
Public biotech trial delays
Cross-sponsor watch for Phase 2/3 primary-completion-date moves on listed biotech companies. Correlated with SEC EDGAR disclosures for investor signal.
Load template →
Custom
Build your own
Mix drugs, sponsors, conditions, NCT IDs. Daily brief. PDF / CSV export. Share with your team.
Unlock Pro